| Assessment Status | Rapid Review Complete |
| HTA ID | 26030 |
| Drug | Mepolizumab |
| Brand | Nucala® |
| Indication | Mepolizumab (Nucala®) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA))^. |
| Assessment Process | |
| Rapid review commissioned | 29/06/2026 |
| Rapid review completed | 17/08/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mepolizumab for this indication, compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
^The Applicant is applying for reimbursement in a subpopulation of the licensed population: patients with uncontrolled COPD (defined as at least two moderate or at least one severe historical exacerbation within 12 months) and an eosinophilic phenotype (defined as ≥ 300 cells/ microlitre) and who are on a combination of an ICS, a LABA and a LAMA.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here